Human Molecular Genetics Advance Access originally published online on August 19, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Human Molecular Genetics, 2003, Vol. 12, Review Issue 2 R293-R301
DOI: 10.1093/hmg/ddg285
© 2003 Oxford University Press
Disorders of mitochondrial protein synthesis
Institute of Medical Technology and Tampere University Hospital, University of Tampere, Finland and Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, UK
Received August 7, 2003; Accepted August 13, 2003
Mitochondrial tRNA gene mutations, including heteroplasmic deletions that eliminate one or more tRNAs, as well as point mutations that may be either hetero- or homoplasmic, are associated with a wide spectrum of human diseases. These range from rare syndromic disorders to cases of commoner conditions such as sensorineural deafness or cardiomyopathy. The disease spectrum of mutations in a given gene, or even a single mutation, may vary, but some patterns are evident, for example the prominence of cardiomyopathy resulting from tRNAIle defects, or of MERFF-like disease from tRNALys defects. Molecular studies of many laboratories have reached a consensus on molecular mechanisms associated with these mutations. Although precise details vary, loss of translational function of the affected tRNA(s) seems to be the final outcome, whether by impaired pre-tRNA processing, half-life, base-modification or aminoacylation. However, a mechanistic understanding of the consequences of this for the assembly and function of the mitochondrial OXPHOS complexes and for the physiological functions of the affected tissues is still a distant prospect. This review presents some views of possible downstream consequences of specific tRNA deficiencies.
* To whom correspondence should be addressed at: Institute of Medical Technology, FIN-33014 University of Tampere, Finland. Tel: +358 32157731; Fax: +358 32157710; E-mail: howy.jacobs{at}uta.fi
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. Messmer, A. Gaudry, M. Sissler, and C. Florentz Pathology-related mutation A7526G (A9G) helps in the understanding of the 3D structural core of human mitochondrial tRNAAsp RNA, August 1, 2009; 15(8): 1462 - 1468. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Rossmanith, M. Freilinger, J. Roka, T. Raffelsberger, K. Moser-Their, D. Prayer, G. Bernert, and R. Bittner Isolated cytochrome c oxidase deficiency as a cause of MELAS BMJ Case Reports, January 22, 2009; 2009(jan21_1): bcr0820080666 - bcr0820080666. [Abstract] [Full Text] |
||||
![]() |
H. Park, E. Davidson, and M. P. King Overexpressed mitochondrial leucyl-tRNA synthetase suppresses the A3243G mutation in the mitochondrial tRNALeu(UUR) gene RNA, November 1, 2008; 14(11): 2407 - 2416. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nozaki, N. Matsunaga, T. Ishizawa, T. Ueda, and N. Takeuchi HMRF1L is a human mitochondrial translation release factor involved in the decoding of the termination codons UAA and UAG. Genes Cells, May 1, 2008; 13(5): 429 - 438. [Abstract] [Full Text] [PDF] |
||||
![]() |
W Rossmanith, M Freilinger, J Roka, T Raffelsberger, K Moser-Thier, D Prayer, G Bernert, and R E Bittner Isolated cytochrome c oxidase deficiency as a cause of MELAS J. Med. Genet., February 1, 2008; 45(2): 117 - 121. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M.C. Janssen, P. J. Hensbergen, F. J. van Bussel, C. I.A. Balog, J. A. Maassen, A. M. Deelder, and A. K. Raap The A3243G tRNALeu(UUR) mutation induces mitochondrial dysfunction and variable disease expression without dominant negative acting translational defects in complex IV subunits at UUR codons Hum. Mol. Genet., October 15, 2007; 16(20): 2472 - 2481. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Putz, B. Dupuis, M. Sissler, and C. Florentz Mamit-tRNA, a database of mammalian mitochondrial tRNA primary and secondary structures RNA, August 1, 2007; 13(8): 1184 - 1190. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Antonicka, F. Sasarman, N. G. Kennaway, and E. A. Shoubridge The molecular basis for tissue specificity of the oxidative phosphorylation deficiencies in patients with mutations in the mitochondrial translation factor EFG1 Hum. Mol. Genet., June 1, 2006; 15(11): 1835 - 1846. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kirino, T. Yasukawa, S. K. Marjavaara, H. T. Jacobs, I. J. Holt, K. Watanabe, and T. Suzuki Acquisition of the wobble modification in mitochondrial tRNALeu(CUN) bearing the G12300A mutation suppresses the MELAS molecular defect Hum. Mol. Genet., March 15, 2006; 15(6): 897 - 904. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. A. Kondrashov Prediction of pathogenic mutations in mitochondrially encoded human tRNAs Hum. Mol. Genet., August 15, 2005; 14(16): 2415 - 2419. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kirino, Y.-i. Goto, Y. Campos, J. Arenas, and T. Suzuki Specific correlation between the wobble modification deficiency in mutant tRNAs and the clinical features of a human mitochondrial disease PNAS, May 17, 2005; 102(20): 7127 - 7132. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J.H. Coenen, H. Antonicka, C. Ugalde, F. Sasarman, R. Rossi, J.G.A.M. A. Heister, R. F. Newbold, F. J.M.F. Trijbels, L. P. van den Heuvel, E. A. Shoubridge, et al. Mutant Mitochondrial Elongation Factor G1 and Combined Oxidative Phosphorylation Deficiency N. Engl. J. Med., November 11, 2004; 351(20): 2080 - 2086. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kirino, T. Yasukawa, S. Ohta, S. Akira, K. Ishihara, K. Watanabe, and T. Suzuki Codon-specific translational defect caused by a wobble modification deficiency in mutant tRNA from a human mitochondrial disease PNAS, October 19, 2004; 101(42): 15070 - 15075. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Levinger, M. Morl, and C. Florentz Mitochondrial tRNA 3' end metabolism and human disease Nucleic Acids Res., October 11, 2004; 32(18): 5430 - 5441. [Abstract] [Full Text] [PDF] |
||||







